Overcoming Barriers in Parkinson’s Disease Trial & Endpoint Development Through Statistics

• Designing smarter clinical trials for slowly progressing Parkinson’s populations, reducing operational hurdles while improving feasibility and signal detection
• Optimizing endpoint selection with robust statistical frameworks that reflect disease biology and patient reality, supporting regulatory and clinical confidence
• Enabling sponsors to run faster, leaner, and more conclusive studies that unlock disease-modifying therapies for patients sooner

VIRTUAL

Speakers:

Nima Shariati

Senior Biostatistician & Team Lead - Project Data Science

Roche